<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15858471
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     04
    </month>
    <day>
     28
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     04
    </month>
    <day>
     21
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1097-6787
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       52
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        May
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of the American Academy of Dermatology
     </title>
     <isoabbreviation>
      J. Am. Acad. Dermatol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies.
    </articletitle>
    <pagination>
     <medlinepgn>
      810-22
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To compare the efficacy and safety of tacrolimus ointment and pimecrolimus cream in adult and pediatric patients with mild to very severe atopic dermatitis (AD).
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      One thousand and sixty-five patients were randomized to treatment in 3 multicenter, randomized, investigator-blinded, 6-week studies.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Based on the Eczema Area Severity Index (EASI), tacrolimus ointment was more effective than pimecrolimus cream at the end of the study in adults (54.1% vs. 34.9%, respectively; P &lt; .0001), in children with moderate/severe disease (67.2% vs. 56.4%, respectively; P = .04), in the combined analysis (52.8% vs. 39.1%, respectively; P &lt; .0001), and at week 1 in children with mild disease (39.2% vs. 31.2%, respectively; P = .04). Tacrolimus was also more effective than pimecrolimus based on the Investigator Global AD Assessment (IGADA), improvement in percentage of total body surface area affected, and improvement in itch scores (P &lt; or = .05), with a faster onset of action. There was no significant difference in the incidence of adverse events (AEs), including application site reactions in the 2 studies involving 650 children. Adults treated with tacrolimus experienced a greater number of local application site reactions on day 1; both groups reported a similar incidence of application site reactions thereafter. More pimecrolimus-treated patients than tacrolimus-treated patients withdrew from the studies because of a lack of efficacy (P &lt; or = .03) or adverse events (P = .002; pediatric mild).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Tacrolimus ointment is more effective and has a faster onset of action than pimecrolimus cream in adults and children with AD; their safety profiles are similar.
     </abstracttext>
    </abstract>
    <affiliation>
     Northwestern University Medical School/Children's Memorial Hospital, Chicago, Illinois 60611-2923, USA. apaller@northwestern.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Paller
      </lastname>
      <forename>
       Amy S
      </forename>
      <initials>
       AS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lebwohl
      </lastname>
      <forename>
       Mark
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fleischer
      </lastname>
      <forename>
       Alan B
      </forename>
      <initials>
       AB
      </initials>
      <suffix>
       Jr
      </suffix>
     </author>
     <author validyn="Y">
      <lastname>
       Antaya
      </lastname>
      <forename>
       Richard
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Langley
      </lastname>
      <forename>
       Richard G
      </forename>
      <initials>
       RG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kirsner
      </lastname>
      <forename>
       Robert S
      </forename>
      <initials>
       RS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Blum
      </lastname>
      <forename>
       Robin R
      </forename>
      <initials>
       RR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rico
      </lastname>
      <forename>
       M Joyce
      </forename>
      <initials>
       MJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Jaracz
      </lastname>
      <forename>
       Eileen
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Crowe
      </lastname>
      <forename>
       Andrew
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Linowski
      </lastname>
      <forename>
       Gregory J
      </forename>
      <initials>
       GJ
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       US/Canada Tacrolimus Ointment Study Group
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Am Acad Dermatol
    </medlineta>
    <nlmuniqueid>
     7907132
    </nlmuniqueid>
    <issnlinking>
     0190-9622
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Ointments
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      pimecrolimus
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      109581-93-3
     </registrynumber>
     <nameofsubstance>
      Tacrolimus
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dermatitis, Atopic
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ointments
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Satisfaction
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tacrolimus
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      4
     </month>
     <day>
      29
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      4
     </month>
     <day>
      25
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      4
     </month>
     <day>
      29
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     S019096220404229X
    </articleid>
    <articleid idtype="doi">
     10.1016/j.jaad.2004.12.038
    </articleid>
    <articleid idtype="pubmed">
     15858471
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

